StockData
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. (ANTX) stock

ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$4.55+0.11 (+2.48%)

Close on Nov 13, 2026Market cap $171.70MP/E –Yield –

AN2 Therapeutics statistics

59 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
Mar 16, 2027 (estimated, after the close)
Last ex-dividend date
No dividends
Fundamentals through
Sep 30, 2026
Share price as of
Nov 13, 2026

Valuation ratiosIndustry

Market Cap
$171.70M
$272.32M
Enterprise Value
$107.30M
$146.23M
PB Ratio
2.27
2.00
P/TBV Ratio
2.27
2.22

Share statisticsIndustry

Shares Change (YoY)
29.0%
10.8%
Shares Change (QoQ)
4.35%
0.50%
Float
30M
49M
Shares Held by Insiders
20.2%
11.7%
Shares Held by Institutions
65.1%
56.4%

Short sellingIndustry

Short Interest
2M
–
Short Interest Change
-15.5%
-0.80%
Short % of Float
8.11%
9.01%
Short % of Shares Outstanding
6.47%
6.30%
Days to Cover
9.18
5.15

Stock price statisticsIndustry

52-Week High
$7.19
–
52-Week Low
$1.00
–
20-Day Moving Average
$4.07
–
50-Day Moving Average
$4.61
–
200-Day Moving Average
$4.22
–
Average True Range (14)
$0.37
–
Price Change (1 Week)
13.8%
-1.15%
Price Change (1 Month)
26.4%
-4.87%
Price Change (3 Months)
-20.6%
-21.0%
Price Change (6 Months)
-4.21%
-20.6%
Price Change (YTD)
299.1%
-23.6%
Price Change (1 Year)
285.6%
-22.4%
Price Change (3 Years)
-71.4%
-29.5%
Average Volume (10 Days)
234,310
–
Average Volume (20 Days)
251,122
–
Average Volume (90 Days)
251,834
–
Relative Volume
0.82
0.70
Relative Strength Index (14)
56.0
43.4
Volatility (1 Year)
133.9%
80.1%
Beta (5 Years)
0.92
1.07

Returns on capitalIndustry

Return on Equity (ROE)
-51.3%
-49.9%
Return on Assets (ROA)
-46.7%
-40.6%
Return on Invested Capital (ROIC)
-618.4%
-32.9%
Return on Capital Employed (ROCE)
-49.5%
-37.9%

Financial positionIndustry

Current Ratio
10.48
3.30
Quick Ratio
10.26
2.39

EfficiencyIndustry

Profits Per Employee
-$1.66M
-$689.41K
Employee Count
21
74
WACC
9.71%
10.2%

Income statement (TTM)Industry

Operating Income
-$37.44M
-$21.37M
Net Income
-$34.84M
-$22.35M
EBITDA
-$37.44M
-$17.21M
EPS (Diluted)
-$0.93
-$0.76

Balance sheetIndustry

Net Cash (Debt)
$64.40M
$17.76M
Net Cash Per Share
$1.71
$0.80
Equity (Book Value)
$75.51M
$53.89M
Book Value Per Share
$2.00
$1.50
Tangible Book Value
$75.51M
$27.13M
Working Capital
$59.49M
$79.99M

Cash flow (TTM)Industry

Operating Cash Flow
-$30.41M
-$12.38M

Dividends and yieldsIndustry

Earnings Yield
-20.3%
-21.8%

Scores and fair valueIndustry

Altman Z-Score
10.78
0.23
Piotroski F-Score
1
4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodANTXS&P 500DifferenceANTX per yearS&P 500 per year
1 month+26.4%-3.0%+29.4 pts
3 months-23.9%-2.8%−21.1 pts
Year to date+299.1%+11.5%+287.6 pts
1 year+302.7%+13.5%+289.2 pts
3 years-69.6%+77.7%−147.3 pts-32.8%+21.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

2M ANTX shares were sold short on Oct 30, 2026, down 15.5% from the previous report, or 8.11% of the shares available to trade. At recent volumes it would take 9.2 days to buy them back. Over the last 20 sessions, 63.9% of the volume reported to FINRA was short selling.

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 20262,440,372-15.5%265,7579.2
Oct 15, 20262,887,692+15.9%390,8117.4
Sep 30, 20262,491,971+3.9%261,1609.5
Sep 15, 20262,397,307-4.4%203,31411.8
Aug 31, 20262,507,571+12.8%217,47111.5
Aug 14, 20262,223,166-6.5%219,62910.1
Jul 31, 20262,377,829-2.4%161,15914.8
Jul 15, 20262,435,644+26.6%246,0309.9
Jun 30, 20261,923,757+47.3%670,2982.9
Jun 15, 20261,305,874+8.1%188,8776.9
May 29, 20261,207,503+44.4%223,9055.4
May 15, 2026836,372-4.9%240,7083.5

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?